Phase 1RecruitingAge-related condition
A Phase I Study in Healthy Volunteers and Parkinson's Disease (PD) Patients.
A Multi-part, Adaptive Phase 1, First Time in Human Study in Healthy Volunteers to Assess Safety, Tolerability and Pharmacokinetics (PK) Following Single Ascending Dose (SAD) and Multiple Ascending Doses (MAD) of MTX325, Including Option to Assess: a Single Dose in Elderly Participants; Multiple Doses in Patients With Parkinson's Disease (PD); Central Nervous System (CNS) Penetration, Biodistribution, and Biomarkers; and the Effect of Food on PK.
- Sponsor
- Mission Therapeutics (Research network)
- Enrolment
- 106 planned
- Conditions
- Parkinson's Disease (PD); Mild to Moderate Parkinson's Disease; Early Stage Parkinson's Disease
- Interventions
- MTX325; Placebo
- Ages
- adults, older adults
- Registry
- NCT07630545
Full record on ClinicalTrials.gov
From the registry
The goal of this trial is to learn if MTX325 can be developed as a potential disease-modifying treatment for Parkinson's Disease. Parts 1-4 complete, Part 5 (multiple doses in patients with Parkinson's Disease) in progress.
Primary outcomes
- Safety and Tolerability
- Brain Biodistribution
History
Study completion expected
Primary completion expected
Last registry update
Registered
Started